GSK to Acquire Trispecific T Cell-Engager for Multiple Myeloma in Deal Worth Up to $750M
GSK sits 27% above its 52-week low of $39.29.
Summary
GSK announced an agreement to acquire a trispecific T cell-engager for multiple myeloma from Chimagen Biosciences, with a total potential deal value of up to $750 million. The programme is expected to enter phase I trials in 2027.
Key Events · M&A and Partnerships · GSK
-
Acquisition of Trispecific TCE
GSK entered an agreement to acquire a trispecific T cell-engager for multiple myeloma from Chimagen Biosciences, securing full global rights.
-
Deal Value Up to $750M
The agreement has a total potential value of up to $750 million, comprising an upfront fee plus success-based development and commercial milestone payments.
-
Phase I Entry Expected 2027
The programme is expected to enter phase I clinical trials in 2027, with the asset designed to improve tolerability versus existing TCEs.
-
Builds on Existing Chimagen Relationship
This follows GSK's prior agreement to acquire CMG1A46, a clinical-stage dual CD19/CD20-targeted TCE from Chimagen.
Analysis · GSK · Life Sciences
GSK is paying an upfront fee plus success-based milestones to secure full global rights to a trispecific T cell-engager from Chimagen Biosciences, with the programme expected to enter phase I trials in 2027. The deal strengthens GSK's blood cancer portfolio and builds on an existing relationship with Chimagen, but the asset is preclinical and the total potential value of up to $750 million is modest relative to GSK's size. The transaction is subject to customary closing conditions.
How filings like this one have moved
In the 30 days to Oct 13, 2026, 29.1% of the 1500 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.51%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $50.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $100.3B. The 52-week trading range was $39.29 to $61.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.